FDA requests additional time for Flexion's sNDA; Genentech releases data for PhIII study of Rituxan
→ In 2017, the FDA greenlighted Flexion Therapeutics‘ intra-articular therapy, Zilretta, designed as a treatment for osteoarthritis-related knee pain. Now, two years later, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
